ClinicaliQ Trial Snapshot
- A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors — Recruiting • Phase I • Oncology • NCT06914128.
- BAY 3713372 is a novel PRMT5 inhibitor being tested in a first-in-human trial to treat MTAP-deleted solid tumors, designed to selectively target cancer cells whilst sparing normal tissues through synthetic lethality.
- Eligible participants have histologically/cytologically confirmed MTAP-deleted solid tumors (various cancer types); study assesses safety, tolerability, and pharmacokinetics across escalating dose cohorts in treatment-Phase Iïve or previously treated patients.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The study treatment, BAY 3713372, is under development to treat MTAP (methylthioadenosine phosphorylase)-deleted solid tumors. It is thought to work by blocking the protein arginine N-methyltransferase 5 (PRMT5). This may kill the MTAP-deleted cancer cells while sparing the normal cells. The main objective of this first-in-human study is to learn how safe BAY 3713372 is, how the body processes it, and how well it works in people with MTAP-deleted solid tumors. For this, the researchers will study and analyze: * the number of participants who have adverse events (AEs) after…
Eligibility Snapshot
- : * Participant must be ≥ 18 years old of age, or the legal age of consent in the jurisdiction of the country in which the study takes place, at the time of signing the informed consent. * At least one measurable lesion that would qualify as target lesion by Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1). * Homozygous MTAP-deletion identified through molecular testing from a locally certified laboratory. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.